21世纪经济报道记者王峰 北京报道 企业出海，风险防控需前置。 《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》指出，有效实施对外投资管理，健 全海外综合服务体系，促进贸易投资一体化，引导产业链供应链合理有序跨境布局。 近日，"企业'走出去'的法律风险及防控研讨会"暨北京企业法律风险防控研究会2025年年会召开。来自 法学界、企业界、律师界的专家，探讨了推动企业安全稳健"走出去"的有效路径。 "随着全球治理体系的深刻变革，国际规则博弈日趋激烈，企业'走出去'已进入更加注重运用规则、参 与规则构建的新阶段。" 北京企业法律风险防控研究会会长彭新林说。 未来，中国将健全国际商事调解、仲裁、诉讼等机制，打造国际商事争议解决优选地。 复杂多样的海外经营法律风险 企业"走出去"主要面临哪些风险？ 安徽师范大学法学院教授奚玮指出，随着国内法律法规的完善，加之税务、金融、环保等领域监管力度 加大，企业同时面临跨境经营不同国家法律体系、监管标准的显著差异。双重合规要求对企业提出了更 高挑战。 从社会层面看，社会公众对"走出去"企业的关注已从经济效益转向合规责任、社会责任等多重维度。互 联网的普及使企业跨境经营行为 ...

Core Viewpoint - Aopu Mai's stock price has experienced fluctuations, with a current decline of 2.01% and a year-to-date increase of 59.83%, indicating volatility in the market while showing strong annual growth in revenue and profit [1][2]. Company Overview - Aopu Mai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company is located in Shanghai and specializes in cell culture products and services [1]. - The revenue composition of Aopu Mai is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1]. Financial Performance - For the period from January to September 2025, Aopu Mai reported a revenue of 272 million yuan, representing a year-on-year growth of 25.79%. The net profit attributable to the parent company was 49.43 million yuan, showing an impressive increase of 81.48% year-on-year [1]. - Since its A-share listing, Aopu Mai has distributed a total of 173 million yuan in dividends [2]. Shareholder Information - As of September 30, 2025, Aopu Mai had 3,682 shareholders, an increase of 14.63% from the previous period. The average number of circulating shares per shareholder rose by 27.96% to 30,838 shares [1]. - Among the top ten circulating shareholders, notable increases were observed in holdings by institutional investors such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [2].

Group 1 - The company, Shenzhen Weiguang Biological Products Co., Ltd., received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific object issuance of A-shares on October 28, 2025 [1] - The company, along with relevant intermediaries, conducted a thorough review and response to the questions raised in the inquiry letter, updating the content of the fundraising prospectus and related application documents accordingly [1] - The financial data in the fundraising documents was updated in line with the company's third-quarter report for 2025, which has already been disclosed [1] Group 2 - The issuance of A-shares is subject to approval by the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, indicating uncertainty regarding the approval process and timeline [2] - The company will fulfill its information disclosure obligations based on the progress of this matter, urging investors to make cautious decisions and be aware of investment risks [2]

证券日报网讯天坛生物11月18日在互动平台回答投资者提问时表示，血液制品产品从血浆采集到实现销 售收入需要经过检疫、生产、检验、批签发等相关工作，需要一定的时间周期，2024年，公司全年实现 采集血浆约2781吨，同比增长15.15%。公司持续深化生产精细化管理，严格执行生产计划，确保血浆 应投尽投，产品应交尽交，保障产品市场供应；同时，通过加强市场拓展，提高产品终端覆盖率、提高 产品销量。 （文章来源：证券日报） ...

证券日报网讯天坛生物11月18日在互动平台回答投资者提问时表示，公司密切关注市场动态，及时分析 研判，适时调整销售策略。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯正海生物11月17日发布公告，在公司回答调研者提问时表示，公司对于研发投入的总体要 求是以战略需求为导向的，公司会结合技术开发方向上的选择和总体产品布局需求等因素综合制定研发 投入规划，确保研发投入充分服务于公司总体战略及公司成长。 ...

安旭生物公告，马华祥持股1477.34万股，占总股本11.62%，拟自公告披露之日起15个交易日后的3个月 内，通过集中竞价减持不超过120万股，不超总股本0.94%，且任意连续90个自然日内减持不超1.00%。 ...

康华生物公告，公司股东孙晚丰于2025.08.18-2025.11.17通过集中竞价减持26909股，减持价格区间86- 90元/股，减持均价86.22元/股，减持比例0.0207%；李声友同期通过集中竞价减持10.26万股，减持价格 区间74.8-89.5元/股，减持均价82.79元/股，减持比例0.0790%。本次减持计划期限已届满。 ...

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Core Viewpoint - 甘李药业's stock has experienced fluctuations, with a year-to-date increase of 49.24% and a recent decline of 9.25% over the past 20 days, indicating volatility in its market performance [1][2]. Financial Performance - For the period from January to September 2025, 甘李药业 reported a revenue of 3.047 billion yuan, representing a year-on-year growth of 35.73%. The net profit attributable to shareholders was 818 million yuan, reflecting a significant increase of 61.32% compared to the previous year [2]. - The company has distributed a total of 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for 甘李药业 increased to 94,700, marking a rise of 22.53%. The average number of circulating shares per shareholder decreased by 17.81% to 5,889 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 8.0042 million shares, an increase of 494,300 shares from the previous period [3].